Bibliography
- Strohl WR, Strohl LM. Therapeutic antibody engineering: current and future advances driving the strongest growth area in the pharma industry. Woodhead Publishing Series in Biomedicine No. 11 Woodhead Publishing; Cambridge: 2012
- Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012;4:413-15
- Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008;20:471-8
- Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther 2012;12:873-90
- Weidle UH, Schneider B, Georges G, Brinkmann U. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics 2012;9:357-72
- Raju TS, Briggs JB, Chamow SM, et al. Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry 2001;40:8868-76
- Spadaro A, Lubrano E, Ferrara N, Scarpa R. Etanercept in psoriatic arthritis. J Rheumatol Suppl 2012;89:74-6
- Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012;899:1-26
- Labrijn AF, Meesters JI, de Goeij BE, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA 2013;110:5145-50
- Jakob CG, Edalji R, Judge RA, et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule. MAbs 2013;5:358-63
- Günther G, Dreger B. Post-marketing observational study on 5% intravenous immunoglobulin therapy (Alphaglobin®/Flebogamma®) in secondary immunodeficiency with recurrent serious bacterial infections. Microbiol Immunol. 2013; doi:10.1111/1348-0421.12060
- Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010;30(Suppl 1):S9-14
- Polat ZA, Walochnik J, Obwaller A, et al. Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. Clin Experiment Ophthalmol 2013; doi:10.1111/ceo.12120
- Olender S, Wilkin TJ, Taylor BS, Hammer SM. Advances in antiretroviral therapy. Top Antivir Med 2012;20:61-86
- Meng Q, Garcia-Rodriguez C, Manzanarez G, et al. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem 2012;430:141-50
- Haurum JS. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Drug Discov Today 2006;11:655-60
- Skartved NJ, Jacobsen HJ, Pedersen MW, et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011;17:5962-72
- Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115(3):489-95
- Raut AS, Prabhu RH, Patravale VB. Psoriasis clinical implications and treatment: a review. Crit Rev Ther Drug Carrier Syst 2013;30:183-216
- Koefoed K, Steinaa L, Søderberg JN, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011;3:584-95